QUINTESSENTIAL-2

A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma

  • 188466

Sorting 24 by

Vancouver General Hospital
Vancouver, BC
  • Not yet accepting
Ochsner LSU Health Shreveport
Ochsner Louisiana State University
Shreveport, LA
  • Accepting patients
Sylvester Comprehensive Cancer Center (Main)
University of Miami Health System
Miami, FL
  • Accepting patients
Winship Cancer Institute
Emory University
Atlanta, GA
  • Accepting patients
Medical College of Wisconsin
Froedtert Hospital
Milwaukee, WI
  • Accepting patients
Tom Baker Cancer Centre
Alberta Health Services
Calgary, AB
  • Not yet accepting
MUSC Hollings Cancer Center
Medical University of South Carolina
Charleston, SC
  • Not yet accepting
Juravinski Cancer Centre
Juravinski Hospital
Hamilton, ON
  • Not yet accepting

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 864-8426

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.